A 12-week, multicenter, open-label, single-arm study to evaluate the effects of fesoterodine on treatment satisfaction and symptom relief in overactive bladder patients.

Trial Profile

A 12-week, multicenter, open-label, single-arm study to evaluate the effects of fesoterodine on treatment satisfaction and symptom relief in overactive bladder patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Feb 2009 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 13 Feb 2009 Primary outcome amended as reported by ClinicalTrials.gov.
    • 13 Feb 2009 Actual number of patients changed from 595 to 516 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top